|Monday, April 21, 2014
You are here: Home » Business » BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Surged by 7.1% to $83 In Pre-Market Trading

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Surged by 7.1% to $83 In Pre-Market Trading 

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) added following the announcement of DealReporter that Roche Holding Ltd (VTX:ROG) is assembling $15 billion in debt financing for an acquisition of the producer of drugs to treat unusual diseases. DealReporter reported, citing people familiar with the situation that Roche possibly will have to pay $95 to $105 per share for the Novato, California-based company. A 23 percent premium to BioMarin’s finishing level yesterday of $77.49 would be the lower end of that range, and would value the company at almost $13.5 billion.

BioMarin surged by 7.1 percent to $83 in New York in pre-market trading. Roche, the world’s largest producer of cancer drugs, has jumped by 0.9 percent to 239.90 Swiss francs. Silvia Dobry, a spokeswoman for the Basel, Switzerland-based company, refused to say anything about DealReporter article.

DealReporter said that UBS AG (VTX:UBSN) has illustrated it will lend $5 billion to Roche for the acquisition, leading the financing. DealReporter further the report that Citigroup Inc. is counseling Roche on the possible sale. However, JPMorgan Chase & Co. (JPM) and Goldman Sachs Group Inc. may support in financing.

In July, people familiar with the matter said that Roche taken into account a bid for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), another producer of medicines for rare diseases. The people said at the time that Alexion involved Goldman as an adviser to get ready for a possible bid from Roche. Companies like Alexion and BioMarin produce medicines for as little as 5,000 to 10,000 patients globally, and charge as much as $400,000 a patient a year.

The rare medicines for small patient populations, identified as orphan drugs obtain special marketing rights as a benefit for their development in the U.S. and Europe, however, the small patient populations indicate smaller number of participants are required for clinical trials. They have drawn the concern of large pharmaceutical companies seeking to avoid a decline in sales as patents on blockbuster drugs die.BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares moved up 1.49% to $78.65.
Looking for the next Rising Stock? Many companies are often too expensive by the time they hit the news. Start looking early for undiscovered companies with huge potential and you can make 300%+ easily.

Read More: Find Out The Next Biggest Cannabis Play

Personal Capital help investors create an optimal portfolio based on your risk profile and help you save fees. Learn More by Clicking Here.

About the author: Mark Cooper

Mark Cooper is a deputy editor for eFInanceHub and is a regular finance contributor. Prior to his current post, Mr. Cooper was a front page editor from 2007 through April 2010. Born in Lubbock, Texas, Mr. Cooper earned a bachelor's degree in journalism from the University of Missouri at Columbia, graduating first in the journalism school. While at the university, he was a reporting intern at the Killeen (Texas) Daily Herald, a Dow Jones Newspaper Fund editing intern at the Boston Globe and a recipient of the Donald J. Reynolds Award, a scholarship for journalism achievement. Contact Mark via email at MCooper@eFinanceHub.com.

Add a Comment

You must be logged in to post a comment.

Fatal error: Call to undefined function newsletter_withcross() in /home/efinance/public_html/wp-content/themes/local-news/localnews/single.php on line 14